Abilify Manufacturing Site Withdrawn In Response To "Approvable" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb withdrew its proposed finished dosage manufacturing facility for Abilify in Mayaguez, Puerto Rico, six weeks before approval of the antipsychotic.